Tissue-Specific Mutations in BRAF and EGFR Necessitate Unique Therapeutic Approaches.

doi:10.1016/j.trecan.2016.10.015

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Tissue-Specific Mutations in BRAF and EGFR Necessitate Unique Therapeutic Approaches.

Trends in cancer - 1 Dec 2016

Foster Scott A, Klijn Christiaan, Malek Shiva

Abstract excerpt

A predominant number of cancers are driven by mutations of key growth signaling genes. While it might be expected that the same alterations within a given oncogene would be identified in all tissues, there are clear cases of tissue specificity. Here, we highlight the tissue specificity of BRAF and EGFR alterations and implications for therapeutic targeting.

Topics

ErbB Receptors
Humans
Mutation
Neoplasms
Proto-Oncogene Proteins B-raf

Source

Open in PubMed

Identifiers

PMID: 28741516
DOI: 10.1016/j.trecan.2016.10.015

Genes

BRAF
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics